O-6-methylguanine-DNA methyltransferase promoter methylation can change in glioblastoma recurrence due to intratumor heterogeneity

Background and Aim: The standard-of-care for patients with glioblastoma (GBM) is surgery followed by concurrent chemotherapy with temozolomide and radiotherapy. O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is commonly assessed in GBM as a predictive marker of response to temoz...

Full description

Bibliographic Details
Main Authors: Valeria Barresi, Maria Caffo, Giuseppa De Luca, Giuseppe Giuffrè
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Glioma
Subjects:
IDH
Online Access:http://www.jglioma.com/article.asp?issn=2589-6113;year=2018;volume=1;issue=6;spage=208;epage=213;aulast=Barresi